Jump to content
  • 0

Candle Countdown Time


Guest Ben

Question

Is there any way to set up a a candle countdown timer, something similar to Trading View where you can see without doing the math that there might be 1 hour 43 minutes remaining on the current 4hr candle?

Link to comment

8 answers to this question

Recommended Posts

  • 0
On 24/05/2020 at 22:18, WokMan said:

i would be keen to know the answer to this one too 

 

On 16/04/2020 at 23:32, Guest Ben said:

Is there any way to set up a a candle countdown timer, something similar to Trading View where you can see without doing the math that there might be 1 hour 43 minutes remaining on the current 4hr candle?

 

On 31/08/2020 at 16:44, Guest CyrM4 said:

Also interested in the above question

 

On 23/11/2020 at 19:23, Guest JDogLoves46 said:

+1 would be interested if this function exists. I've looked all round the platform but cannot seem to find it as an option

Glad to see the interest on this one! 

This isn't something we offer however I will put it forward to our new platform developers this week. 

All the best 

Link to comment
  • 0

Any update on this one? 

Just starting to familiarise with the platform and I really miss the candle timer I have with other software!

 

Quote

 

Glad to see the interest on this one! 

This isn't something we offer however I will put it forward to our new platform developers this week. 

All the best 

 

Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • General Statistics

    • Total Topics
      17,286
    • Total Posts
      81,364
    • Total Members
      65,898
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    BethStan
    Joined 25/01/22 07:45
  • Posts

    • Oil Up, Eastern Europe and Middle East Geopolitical Tensions Concerns Continue CommoditiesJan 25, 2022        © Reuters. By Gina Lee Investing.com – Oil was up on Tuesday morning in Asia clawing back some of the previous day’s losses. Concerns are also mounting over potential supply disruptions as geopolitical tensions rise in both Eastern Europe and the Middle East. Brent oil futures gained 0.59% to $85.93 by 10:22 PM ET (3:22 AM GMT) and WTI futures were up 0.46% to $83.69. The black liquid hit seven-year highs during the previous week, boosted by a tightening supply and resurging fuel demand globally. "The market tone stays strong, supported by heightening geopolitical risk," Sunward Trading chief analyst Chiyoki Chen told Reuters. "We saw profit-taking on Monday when the prices moved higher and as Wall Street temporarily sank amid concerns over the U.S. Federal Reserve's policy to reduce economic stimulus, but buying appetite for oil remained solid," Chen added. U.S. shares ended a rollercoaster session on Monday, ending higher after posting heavy losses earlier in the session. Investors turned to safe-haven assets, as uncertainty over geopolitical tensions and Fed monetary policy tightening mounted. U.S.-Russia tensions over Ukraine remain, with NATO saying on Monday that it is putting forces on standby and sending more ships and fighter jets to Eastern Europe. Russia denounced the move as Western "hysteria" over its build-up of troops to the Ukraine border. In the Middle East, Yemen's Houthi movement launched its latest missile attack at the United Arab Emirates (UAE) on Monday. The attack targeted a base hosting the U.S. military but was thwarted by U.S.-built Patriot interceptors, according to U.S. and UAE officials. In the U.S., lower U.S. oil inventories are also giving oil a boost. Crude inventories around the NYMEX WTI delivery point at Cushing in Oklahoma are at their lowest levels for the time of year since 2012. Investors now await crude oil supply data from the American Petroleum Institute, due later in the day. Meanwhile, portfolio investors added to their bullish positions in oil for a fifth consecutive week, with some countries starting to emerge from their latest COVID-19 outbreaks, and governments are beginning to lift business and travel restrictions.
    • Britain says 6,000 more people needed for trial of Merck COVID pill Stock MarketsJan 25, 2022      © Reuters. FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. LONDON (Reuters) - Britain said on Tuesday it needed to recruit 6,000 more people onto a trial of Merck's COVID-19 antiviral pill molnupiravir to inform how the drug can be rolled out more widely. Britain's MHRA medicine regulator approved the pill, made by Merck and Ridgeback Therapeutics, in November, and the government launched a national study to establish the best way to use the drug. The health ministry said that while 4,500 trial participants had signed up, thousands more were needed to gather the data needed. The study, called Panoramic, was launched to assess how the antiviral should be used in a largely vaccinated population, given it was assessed in clinical trials on unvaccinated people. "Antivirals are a hugely important addition to our response to COVID-19," said Eddie Gray, chair of the UK's Antivirals Taskforce. "Getting people enrolled onto this study is vital, not just in protecting the most vulnerable now, but in ensuring we can deploy these medicines more widely as soon as possible." Prime Minister Boris Johnson last week said he would ditch mask mandates, work from home guidance and compulsory COVID passes in England, citing Britain's purchase of antivirals as well as the booster rollout and the lower severity of the Omicron coronavirus variant. The health ministry said it had bought 2.23 million courses of the Merck drug, as well as 2.75 million courses of an antiviral pill developed by Pfizer Inc (NYSE:PFE) which it has not yet started to deploy.   Merck's pill was shown to reduce hospitalisations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness. The government said that over-50s and those with an underlying medical condition who had tested positive for COVID-19 on a PCR test or who were unwell with COVID symptoms in the last five days could sign up for the Panoramic study.
    • The current slide in the stock market may be spooking some investors, but it’s seen as unlikely to scare Federal Reserve officials enough to deviate from their current policy track. In fact, Wall Street is looking at a Fed that might even talk tougher this week as it is seemingly locked in a fight against generational highs in inflation amid market turmoil. Goldman Sachs and Bank of America both have said in recent days that they see increasing chances of an even more hawkish central bank, meaning a better chance of even more interest rate hikes and other measures that would reverse the easiest monetary policy in U.S. history. That sentiment is spreading, and is causing investors to reprice a stock market that had been hitting new historic highs on a consistent basis but has taken a steep turn in the other direction in 2022. “The S&P is down 10%. That’s not enough for the Fed to go with a weak backbone. They have to show some credibility on inflation here,” said Peter Boockvar, chief investment officer at the Bleakley Advisory Group. “By kowtowing to the market so quickly without doing anything with respect to inflation would be a bad look for them.” The Fed will have to be easier on the hawkish talk, says Ed Yardeni Over the past two months the Fed has taken a sharp pivot on inflation, which is running at a nearly 40-year high. Central bank officials spent most of 2021 calling the rapid price increases “transitory” and pledging to keep short-term borrowing rates anchored near zero until they saw full employment. But with inflation more durable and intense than Fed forecasts, policymakers have indicated they will start hiking interest rates in March and tightening policy elsewhere. Where the market had been able to count on the Fed to step in with policy easing during previous corrections, a Fed committed to fighting inflation is considered unlikely to step in and stem the bleeding. “That gets into the circular nature of monetary policy. It gooses asset prices when they are pedal to the metal, and asset prices fall when they back off,” Boockvar said. “The difference this time is they have rates at zero and inflation is at 7%. So they have no choice but to react. Right now, they are not going to roll over for markets just yet.” The Federal Open Market Committee, which sets interest rates, meets Tuesday and Wednesday. Full article CNBC
×
×
  • Create New...